Intensive Care Unit, Hospices Civils de Lyon, CHU Lyon-Sud, Pierre-Bénite, France.
Crit Care Med. 2011 Dec;39(12):2684-90. doi: 10.1097/CCM.0b013e3182282a40.
Septic shock remains a serious disease with high mortality and increased risk of hospital-acquired infection. The prediction of outcome is of the utmost importance for selecting patients for therapeutic strategies aiming to modify the immune response. The aim of this study was to assess the capability of S100A9 messenger RNA in whole blood from patients with septic shock to predict survival and the occurrence of hospital-acquired infection.
Cohort study.
Two intensive care units in a university hospital.
The study included patients with septic shock (n = 166) and healthy volunteers (n = 44).
None.
For the patients with septic shock patients, overall mortality was 38% and the mean Simplified Acute Physiologic Scale II on shock onset was 52. Using quantitative reverse transcriptase-polymerase chain reactions, we found that median S100A9 messenger RNA was significantly lower in healthy volunteers than in patients with septic shock (p < .0001) between days 1 and 3 after onset of the septic shock and not significantly different between nonsurvivor and survivor patients (p = .1278). However, median S100A9 messenger RNA measured on days 7-10 was significantly higher in patients who were about to contract hospital-acquired infections compared with those who were not (p = .009). In the multivariate analysis, the S100A9 marker increased the probability of contracting hospital-acquired infections with an odds ratio of 1.12 per unit (p = .0054).
S100A9 messenger RNA is increased in septic shock and its delayed overexpression is associated with the occurrence of secondary hospital-acquired infection. This biomarker may be of major interest in identifying patients with increased risk of hospital-acquired infection who could benefit from targeted therapy aimed at restoring their immune functions.
脓毒症性休克仍然是一种死亡率高且医院获得性感染风险增加的严重疾病。预测预后对于选择旨在改变免疫反应的治疗策略的患者至关重要。本研究旨在评估脓毒性休克患者全血中 S100A9 信使 RNA 预测存活和发生医院获得性感染的能力。
队列研究。
一所大学医院的两个重症监护病房。
本研究纳入了脓毒性休克患者(n=166)和健康志愿者(n=44)。
无。
对于脓毒性休克患者,总死亡率为 38%,休克发作时简化急性生理评分 II 的平均值为 52。使用定量逆转录-聚合酶链反应,我们发现健康志愿者的 S100A9 信使 RNA 中位数明显低于脓毒性休克患者(p<0.0001),分别在脓毒性休克发作后 1 至 3 天,且幸存者与非幸存者患者之间无显著差异(p=0.1278)。然而,在脓毒性休克发作后第 7 至 10 天测量的 S100A9 信使 RNA 中位数在即将发生医院获得性感染的患者中明显高于未发生感染的患者(p=0.009)。在多变量分析中,S100A9 标志物的表达增加与医院获得性感染的发生呈正相关,单位增加的可能性比为 1.12(p=0.0054)。
S100A9 信使 RNA 在脓毒症性休克中增加,其延迟过度表达与继发性医院获得性感染的发生有关。这种生物标志物可能对识别具有更高医院获得性感染风险的患者具有重要意义,这些患者可能受益于旨在恢复其免疫功能的靶向治疗。